NASDAQ:BABY - Natus Medical Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$32.70 +0.15 (+0.46 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$32.70
Today's Range$32.20 - $32.80
52-Week Range$28.00 - $43.60
Volume6,354 shs
Average Volume215,607 shs
Market Capitalization$1.09 billion
P/E Ratio22.38
Dividend YieldN/A
Beta0.48
Natus Medical logoNatus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders. The company provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. It offers diagnostic electroencephalography (EEG), ambulatory EEG, and long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, intra-operative monitoring, and diagnostic and monitoring transcranial doppler ultrasound technology systems. The company also provides hearing screening products to screen the hearing; diagnostic hearing assessment products to screen for or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems; balance and mobility systems to diagnose and assist in treating balance disorders; and thermoregulation products to control the incubators and warmers. In addition, it offers jaundice management products to treat jaundice; brain injury products to diagnose the severity of brain injury; NICVIEW, a live streaming video for families with babies in the neonatal intensive care unit (NICU); and essential products used in the everyday operation of NICU. Further, the company provides computer-based audiological, otoneurologic, and vestibular instrumentation and sound rooms to hearing and balance care professionals. It serves hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Natus Medical Incorporated was founded in 1987 and is headquartered in Pleasanton, California.

Receive BABY News and Ratings via Email

Sign-up to receive the latest news and ratings for BABY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:BABY
CUSIP63905010
Phone925-223-6700

Debt

Debt-to-Equity Ratio0.31
Current Ratio3.06
Quick Ratio2.28

Price-To-Earnings

Trailing P/E Ratio22.38
Forward P/E Ratio20.19
P/E GrowthN/A

Sales & Book Value

Annual Sales$500.97 million
Price / Sales2.22
Cash Flow$2.5607 per share
Price / Cash12.77
Book Value$13.55 per share
Price / Book2.41

Profitability

EPS (Most Recent Fiscal Year)$1.45
Net Income$-20,290,000.00
Net Margins-4.71%
Return on Equity10.96%
Return on Assets6.71%

Miscellaneous

Employees1,726
Outstanding Shares34,070,000
Market Cap$1,091.94

Natus Medical (NASDAQ:BABY) Frequently Asked Questions

What is Natus Medical's stock symbol?

Natus Medical trades on the NASDAQ under the ticker symbol "BABY."

How will Natus Medical's stock buyback program work?

Natus Medical declared that its Board of Directors has initiated a share buyback program on Thursday, February 22nd 2018, which permits the company to repurchase $30,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board of directors believes its stock is undervalued.

How were Natus Medical's earnings last quarter?

Natus Medical Inc (NASDAQ:BABY) announced its quarterly earnings data on Wednesday, April, 25th. The medical equipment provider reported $0.24 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.24. The medical equipment provider had revenue of $128.60 million for the quarter, compared to the consensus estimate of $125.91 million. Natus Medical had a negative net margin of 4.71% and a positive return on equity of 10.96%. The company's quarterly revenue was up 3.1% compared to the same quarter last year. During the same period last year, the company earned $0.30 EPS. View Natus Medical's Earnings History.

When is Natus Medical's next earnings date?

Natus Medical is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Natus Medical.

What guidance has Natus Medical issued on next quarter's earnings?

Natus Medical updated its FY18 earnings guidance on Wednesday, April, 25th. The company provided earnings per share guidance of $1.60-1.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.62. The company issued revenue guidance of $535-540 million, compared to the consensus revenue estimate of $536.88 million.Natus Medical also updated its Q2 guidance to $0.25-0.27 EPS.

What price target have analysts set for BABY?

3 brokers have issued 1 year price targets for Natus Medical's shares. Their forecasts range from $39.00 to $49.00. On average, they expect Natus Medical's stock price to reach $44.00 in the next year. This suggests a possible upside of 35.4% from the stock's current price. View Analyst Ratings for Natus Medical.

What is the consensus analysts' recommendation for Natus Medical?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natus Medical in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Natus Medical's key competitors?

Who are Natus Medical's key executives?

Natus Medical's management team includes the folowing people:
  • Mr. James B. Hawkins, Pres, CEO & Director (Age 62)
  • Mr. Jonathan A. Kennedy, Exec. VP & CFO (Age 47)
  • Mr. Kenneth M. Traverso, Exec. Officer (Age 57)
  • Dr. D. Christopher Chung, VP of Medical Affairs, Quality & Regulatory Affairs (Age 54)
  • Mr. Austin F. Noll III, VP & GM of Neurology (Age 51)

Has Natus Medical been receiving favorable news coverage?

News articles about BABY stock have trended somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Natus Medical earned a media sentiment score of 0.18 on Accern's scale. They also assigned news coverage about the medical equipment provider an impact score of 44.31 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Natus Medical's major shareholders?

Natus Medical's stock is owned by a number of of institutional and retail investors. Top institutional investors include Confluence Investment Management LLC (2.82%), Fenimore Asset Management Inc. (0.96%), Peregrine Capital Management LLC (0.70%), Cambiar Investors LLC (0.45%), Bank of Montreal Can (0.13%) and Municipal Employees Retirement System of Michigan (0.03%). Company insiders that own Natus Medical stock include Dong Chune Christopher Chung, Doris Engibous, James B Hawkins, Jonathan Kennedy, Ken Ludlum, Robert A Gunst and William M Moore. View Institutional Ownership Trends for Natus Medical.

Which major investors are selling Natus Medical stock?

BABY stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Cambiar Investors LLC, Confluence Investment Management LLC, Municipal Employees Retirement System of Michigan and Bank of Montreal Can. Company insiders that have sold Natus Medical company stock in the last year include Dong Chune Christopher Chung, James B Hawkins, Ken Ludlum, Robert A Gunst and William M Moore. View Insider Buying and Selling for Natus Medical.

Which major investors are buying Natus Medical stock?

BABY stock was acquired by a variety of institutional investors in the last quarter, including Fenimore Asset Management Inc., Penn Davis Mcfarland Inc. and Xact Kapitalforvaltning AB. View Insider Buying and Selling for Natus Medical.

How do I buy shares of Natus Medical?

Shares of BABY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Natus Medical's stock price today?

One share of BABY stock can currently be purchased for approximately $32.50.

How big of a company is Natus Medical?

Natus Medical has a market capitalization of $1.09 billion and generates $500.97 million in revenue each year. The medical equipment provider earns $-20,290,000.00 in net income (profit) each year or $1.45 on an earnings per share basis. Natus Medical employs 1,726 workers across the globe.

How can I contact Natus Medical?

Natus Medical's mailing address is 6701 KOLL CENTER PARKWAY SUITE 120, PLEASANTON CA, 94566. The medical equipment provider can be reached via phone at 925-223-6700 or via email at [email protected]


MarketBeat Community Rating for Natus Medical (NASDAQ BABY)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  206 (Vote Outperform)
Underperform Votes:  214 (Vote Underperform)
Total Votes:  420
MarketBeat's community ratings are surveys of what our community members think about Natus Medical and other stocks. Vote "Outperform" if you believe BABY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BABY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.